NL-OMON28074Not yet recruitingNot Applicable
Detection of Breast Cancer using Folate-FITC Enhanced Optical Imaging in Breast Cancer Patients.
niversity Medical Center Groningen (UMCG), Department of Surgery.0 sites10 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 10
Study Overview
Brief Summary
- Hartmann LC, Keeney GL, Lingle WL et al. Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer 2007; 121:938-942.
2. Sega EI, Low PS. Tumor detection using folate receptor-targeted imaging agents. Cancer Metastasis Rev 2008; 27:655-664.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Women above the age of 21 who have biopsy-proven stage I-II breast cancer and who are planning to undergo lumpectomy as a treatment for their disease. Furthermore, folate receptor (FR) expression of the tumour must be strong (¡Ý2+), as determined by immunohistochemistry prior to surgery.
Exclusion Criteria
- •1. Refusal of the patient to be included in the study;
- •2. Pregnant or breast-feeding;
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Circulating Tumor Cells Screen for Breast CancerBreast NeoplasmNeoplastic Cells, CirculatingNCT05633680Handan First Hospital200
Completed
Phase 1
Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian CancerEndometrial CancerOvarian CancerFallopian CancerPeritoneal CancerNCT01580696COL George Peoples, MD, FACS51
Completed
Phase 2
Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial CarcinomaOvarian CarcinomaRecurrent Endometrial CarcinomaNCT01689714Endocyte16
Completed
Phase 2
Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary TumorsPituitary TumorsNCT01689727Endocyte40
Completed
Not Applicable
FR in Stored PlasmaOvarian CancerNCT00787514Royal Marsden NHS Foundation Trust27